Knee Osteoarthritis Drug Development Pipeline Analysis 2025

DelveInsight's comprehensive "Knee Osteoarthritis Pipeline Insight 2025" analysis delivers thorough insights about over 50 organizations and more than 60 investigational medications within the Knee Osteoarthritis development landscape. The report encompasses drug candidate profiles across both clinical and preclinical phases, offering therapeutic evaluations organized by product category, developmental phase, administration method, and molecular classification. Additionally, it spotlights dormant pipeline candidates in this therapeutic area.

Curious about the latest updates in the Knee Osteoarthritis Pipeline? Click here to explore the therapies and trials making headlines @ Knee Osteoarthritis Pipeline Outlook Report

Major Highlights from the Knee Osteoarthritis Pipeline Analysis

As of December 08, 2025 - Doron Therapeutics Inc. performed a trial to evaluate the efficacy, safety, and tolerability of a single intra-articular injection of PTP-001 compared to placebo over a 52-week period in participants diagnosed with radiographic and symptomatic knee OA.

As of November 24, 2025 - CellSeed Inc. disclosed a Phase III Investigation Evaluating the Efficacy and Safety of CLS2901C in Patients Diagnosed With Osteoarthritis of the Knee. To evaluate the efficacy and safety of CLS2901C human allogenic chondrocyte sheets used in the osteotomy + RMSC group compared to in the osteotomy alone group of patients diagnosed with osteoarthritis of the knee (OAK).

As of November 24, 2025 - Paradigm Biopharmaceuticals Ltd. performed a Phase 3, Randomised, Double-Blind, Placebo-Controlled Multi-Centre Investigation to Evaluate the Treatment Effect of Pentosan Polysulfate Sodium Compared to Placebo in Participants Diagnosed With Knee Osteoarthritis Pain

As of November 13, 2025 - Amzell launched a study where gel will be applied directly to that knee throughout the 6 weeks of the investigation. This represents a multicenter, randomized, double-blind, placebo-controlled, parallel group, 6-week trial of a formulation of AMZ001 once daily versus placebo once daily. Participants will be evaluated for osteoarthritis by X-ray images of the knees and one knee will be selected for treatment as the target knee.

DelveInsight's Knee Osteoarthritis Pipeline analysis reveals a dynamic field with over 50 active organizations advancing more than 60 investigational therapies for Knee Osteoarthritis management.

Premier Knee Osteoarthritis pharmaceutical organizations include Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, and PT. Prodia Stem Cell Indonesia, among others.

Notable Knee Osteoarthritis investigational agents include Civamide, SYN321, Clodronate, LBSA0103, Pelubiprofen CR 45mg tab., Tirzepatide, CLS2901C, RN624 (PF-04383119), Allocetra, RHH646, TLC599, among others.

Want to know which organizations are leading innovation in Knee Osteoarthritis? Dive into the full pipeline insights @ Knee Osteoarthritis Clinical Trials Assessment

The Knee Osteoarthritis Pipeline Analysis delivers disease background, pipeline landscape, and therapeutic evaluation of primary pipeline candidates within this therapeutic domain. The analysis also emphasizes unmet medical needs regarding Knee Osteoarthritis.

Knee Osteoarthritis Disease Background

Osteoarthritis (OA) represents the most common form of arthritis. Some people call it degenerative joint disease or "wear and tear" arthritis. It occurs most frequently in the hands, hips, and knees. With OA, the cartilage within a joint begins to break down and the underlying bone begins to change. These changes usually develop slowly and get worse over time. OA can cause pain, stiffness, and swelling. In some cases it also causes reduced function and disability; some people are no longer able to do daily tasks or work.

Emerging Knee Osteoarthritis Drug Candidates Profile

Lorecivivint: Biosplice Therapeutics

Lorecivivint (SM04690) represents a small-molecule CLK/DYRK1A inhibitor that modulates Wnt and inflammatory pathways and is in development as a potential disease-modifying osteoarthritis drug. Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three potential effects on joint health: reduction of inflammation, slowing of cartilage breakdown, and generation of cartilage. Currently, this drug is in Phase III stage of its development for managing Knee Osteoarthritis.

EP-104IAR: Eupraxia Pharmaceuticals Inc

EP-104IAR is designed to meet the significant unmet medical need and market demand for long-lasting disease relief in multiple indications benefitting from highly localized and longer delivery of corticosteroids. The lead indication is for pain relief in knee OA. With EP-104IAR, Eupraxia hopes to transform the way knee OA pain is managed. Currently approved corticosteroids are very effective at reducing pain for a short duration late in the disease but can expose the body to unwanted local and systemic side effects. EP-104IAR is designed to prolong the duration of pain relief with fewer unwanted side effects. It encapsulates a highly potent corticosteroid (fluticasone propionate) within a microns-thin polymer membrane, part of Eupraxia's patented technology platform. Injected into the knee, EP-104IAR is designed to diffuse the corticosteroid slowly into the knee joint providing local therapeutic concentrations for up to six months. This has the potential dual advantage of providing longer duration of pain relief with fewer systemic side effects. A robust safety and tolerability profile would also benefit the estimated 70% of knee OA patients that experience pain in both knees by allowing simultaneous treatment of both affected joints. Currently, this drug is in Phase II stage of its development for managing Knee Osteoarthritis.

LG00034053: LG Chem

LG34053 represents an injectable new drug with a novel mechanism of blocking the inflammatory pathway and inhibiting chondrocyte apoptosis. LG Chem expects that the new drug will be different from existing symptomatic pain relief drugs. LG00034053 represents the world's first injection-type new drug that blocks inflammatory pathways and inhibits cartilage cell death. Preclinical results demonstrated that the pain relief effect lasted for several months with just one administration, and it also improved effects on cartilage damage, the root cause of arthritis. It has shown the possibility of developing a new drug that is different from existing pain relief symptomatic drugs. Currently, this drug is in Phase I/II stage of its development for managing Knee Osteoarthritis.

If you're tracking ongoing Knee Osteoarthritis Clinical investigations, this analysis is essential reading. Tap to see the breakthroughs @ Knee Osteoarthritis Treatment Drugs

The Knee Osteoarthritis Pipeline Analysis Delivers Insights into:

The analysis provides comprehensive insights about organizations developing therapeutic interventions for Knee Osteoarthritis management with aggregate therapies developed by individual companies for this indication.

It evaluates various therapeutic candidates organized into early-stage, mid-stage, and late-stage development for Knee Osteoarthritis Treatment.

Knee Osteoarthritis pharmaceutical organizations are engaged in targeted therapeutic development with corresponding active and inactive (dormant or discontinued) programs.

Knee Osteoarthritis investigational drugs categorized by developmental phase, administration route, target receptor, monotherapy or combination approach, various mechanisms of action, and molecular classification.

Comprehensive analysis of partnerships (company-company collaborations and company-academic partnerships), licensing agreements, and financial arrangements for future progression of the Knee Osteoarthritis marketplace.

Knee Osteoarthritis Pharmaceutical Organizations

Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, and PT. Prodia Stem Cell Indonesia, among others.

The Knee Osteoarthritis pipeline analysis delivers therapeutic evaluation of pipeline medications by Administration Route. Agents have been classified under various administration routes including:

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Knee Osteoarthritis Products have been organized under various Molecular classifications including:

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

From emerging drug candidates to competitive intelligence, the Knee Osteoarthritis Pipeline Analysis covers it all – check it out now @ Knee Osteoarthritis Market Drivers and Barriers, and Future Perspectives

Coverage of the Knee Osteoarthritis Pipeline Analysis

Coverage: Global

Knee Osteoarthritis Pharmaceutical Organizations: Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, and PT. Prodia Stem Cell Indonesia, among others.

Knee Osteoarthritis Therapeutic Candidates: Civamide, SYN321, Clodronate, LBSA0103, Pelubiprofen CR 45mg tab., Tirzepatide, CLS2901C, RN624 (PF-04383119), Allocetra, RHH646, TLC599, among others.

Knee Osteoarthritis Therapeutic Evaluation by Product Category: Mono, Combination, Mono/Combination

Knee Osteoarthritis Therapeutic Evaluation by Clinical Phases: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what's next for the Knee Osteoarthritis Treatment landscape in this detailed analysis @ Knee Osteoarthritis Emerging Drugs and Major Players

Report Structure

1. Introduction

2. Executive Summary

3. Knee Osteoarthritis: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Knee Osteoarthritis – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Lorecivivint: Biosplice Therapeutics

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. EP-104IAR: Eupraxia Pharmaceuticals Inc

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I/II)

14. LG00034053: LG Chem

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug Name: Company Name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Knee Osteoarthritis Key Companies

21. Knee Osteoarthritis Key Products

22. Knee Osteoarthritis Unmet Needs

23. Knee Osteoarthritis Market Drivers and Barriers

24. Knee Osteoarthritis Future Perspectives and Conclusion

25. Knee Osteoarthritis Analyst Views

26. Knee Osteoarthritis Key Companies

27. Appendix

About DelveInsight

DelveInsight is a prominent healthcare-focused market research and consulting organization that delivers clients with premium market intelligence and analysis to facilitate informed business decisions. With a team of seasoned industry specialists and comprehensive understanding of the life sciences and healthcare industries, we provide customized research solutions and insights to clients worldwide. Connect with us to obtain high-quality, precise, and real-time intelligence to maintain a competitive advantage.

Contact Us

Kanishk

kkumar@delveinsight.com